Generative, context-aware design that dynamically adapts to embedded features within the bioresins. Enhanced viability, complexity and physiological relevance of 3D bioprinted human tissues.

24 September 2025 Berkeley-based Prellis Biologics, Inc., developer of human in vitro antibody generation platform, announces collaboration with Eli Lilly to accelerate the discovery of human antibodies for multiple disease targets. Prellis’ EXIS™ lymph node platform for target‑specific human antibody generation is a shining example of ingenuity by which several technologies were combined to capture human-relevant physiology. The traditional method of antibody generatio

09 December 2025 Riccardo Levato’s team at UMC Utrecht and Utrecht University receives an ERC Consolidator Grant of approx. €2.3M to advance the next phase of its innovative method of generative, context-aware 3D bioprinting. The technique of 3D bioprinting of living tissues to recapitulate the structure and function of human organs has shown great promise in disease modelling, drug testing and regenerative medicine. Supported by a 2020 ERC Starting Grant, Riccardo Levat

12 November 2025 Inventia Life Science's 3D bioprinted patient-derived cancer models has opened the door for Hunter Medical Research Institute to advance its drug repurposing program into Australian New Zealand clinical trials. The drug in question, efavirenz, is known as an antiretroviral NNRTI (non‑nucleoside reverse transcriptase inhibitor) used for treating HIV. Its repurposing has the potential to improve the survival of patients with high-grade serous ovarian cancer